Our Sponsors

  • Pre-Market Stocks to Buy | 06/22/2010 | CYPB | SSCCQ | AFFY |



    quicksilver logo
    Tuesday June 22nd, 2010 at 0752 am EST

    Hot Stocks for Tuesday 06/22/2010  
    CYPB, SSCCQ, AFFY,

    Dear Traders,


    Stocks to Watch Today
    CYPB- Cypress Bioscience, Inc.
    SSCCQ- Smurfit-Stone Container Corporation
    AFFY- Affymax, Inc.


    CYPBCypress stock was under high  pressure which  is likely due to investors viewing the deal as negative in the near-term, with Cypress spending its valuable royalty income on a potentially risky research and development including late-stage patient trials. Stocks were down 37% on Tuesday. Most of it was an over reaction. It is expected that the stock will gain around 15% today. get ready to jump in Pre-Market and sell at high. It is also a good long term investment at this price.
    News
    Cypress buys rights to sell schizophrenia drug
    Cypress said late Sunday it will pay BioLineRx $30 million upfront for the rights, and additional clinical and regulatory milestone payments potentially worth up to $160 million. Under terms of the deal Cypress also could make $175 million in payments to cover sales milestones and approvals for expanded use of the drug.
    Source : AP


    SSCCQ- Shares of SSCCQ will continue their upward trend after the court approved its reorgnization plan. This is an excellent opportunity to multipl your oney. This stock can jump back to $1 within a month.
    News
    Smurfit Stone cleared to exit bankruptcy
    Smurfit Stone Container Corp received court approval on Monday for its reorganization plan, clearing the way for the packaging company to exit bankruptcy later this month. The second-largest containerboard producer in North America and its creditors agreed in May provide about 5 percent of its stock for shareholders as a way to end months of legal battles over the value of its business.
    Source : Reuters 

    AFFY Shares of AFFY are highly under-valued right now. Monday was a nightmare for the company when the stocks lost 68% of their value after the company announced Phase 3 data. The results met primary endpoints with  little difference found in secondary analysis. The Drug will still go forward for NDA application with the FDA. Its a good buying opportunity on Tuesday. Buying in pre-market will be beneficial. 
    News
    Affymax and Takeda Announce Phase 3 Trials Meet Primary Endpoints for Investigational Drug, Hematide™/peginesatide, to Treat Anemia in Chronic Renal Failure With Some Differences Noted in Secondary Analyses
    The primary efficacy endpoint, the mean change in hemoglobin (Hb) from baseline, in each of the four Phase 3 studies (EMERALD 1, EMERALD 2, PEARL 1 and PEARL 2) met the statistical criteria for non-inferiority, when Hematide was compared to epoetin and darbepoetin, in correcting and/or maintaining Hb in the target range. Hematide also met the statistical criterion for non-inferiority in the combined four studies for the adjudicated cardiovascular composite safety endpoint (CSE), which was composed of death, stroke, myocardial infarction, congestive heart failure, unstable angina, and arrhythmia (hazard ratio (HR) 1.06, 90 percent confidence interval (CI) 0.91 – 1.22).
    Source : BusinessWire 

    Work smart Today to enjoy your Tomorrow.

    God Bless,
    Be Rich.
     


0 comments:

Leave a Reply

Latest Posts